BIO Expresses Strong Support for President Obama’s Research and Development Funding Goal
WASHINGTON, D.C. (April 27, 2009) – The following statement was issued by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood regarding today’s announcement by President Barack Obama setting a national goal of devoting more than three percent of U.S. Gross Domestic Product to scientific research and development:
“America’s biotechnology community thanks President Obama for setting this ambitious goal. As the President said, ‘Science is more essential for our prosperity, our security, our health, our environment, and our quality of life than it has ever been.’ We couldn’t agree more.
“Biotechnology is uniquely positioned to fulfill the President’s vision of a robust science sector. The more than 1.3 million Americans in the biosciences are providing advanced therapies and cures for patients suffering from debilitating diseases, developing new energy sources, and enhancing sustainable agriculture. More, our industry can help drive economic growth in innovation industries.
“We look forward to working with the President, the Congress and all other interested parties in continuing U.S. leadership in innovation.”
Upcoming BIO Events
BIO-LES Business Development Basics Course
May 15–17, 2009
BIO-LES Advanced Business Development Course
May 15–17, 2009
BIO Executive Presentation Workshop
May 17, 2009
BIO Human Resources Conference
May 17-19, 2009
2009 BIO International Convention
May 18-21, 2009
June 9-10, 2009
World Congress on Industrial Biotechnology & Bioprocessing
July 19-22, 2009
Montreal, Quebec, Canada
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.